I

Inno-Gene SA
WSE:IGN

Watchlist Manager
Inno-Gene SA
WSE:IGN
Watchlist
Price: 5.04 PLN -0.4% Market Closed
Market Cap: 17.7m PLN

Operating Margin
Inno-Gene SA

-565.6%
Current
-69%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-565.6%
=
Operating Profit
-2.6m
/
Revenue
462k

Operating Margin Across Competitors

No Stocks Found

Inno-Gene SA
Glance View

Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

IGN Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-565.6%
=
Operating Profit
-2.6m
/
Revenue
462k
What is the Operating Margin of Inno-Gene SA?

Based on Inno-Gene SA's most recent financial statements, the company has Operating Margin of -565.6%.

Back to Top